Aveanna Announces Launch of Secondary Offering of Common Stock

Rhea-AI Summary

Aveanna Healthcare (NASDAQ: AVAH) announced on October 21, 2025 that certain selling stockholders affiliated with J.H. Whitney Equity Partners VII have commenced a secondary offering of 10,000,000 shares of common stock, with underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.

The selling stockholders will receive all net proceeds; the company is not offering shares and will not receive any proceeds from the sale. Jefferies and J.P. Morgan are joint lead book-running managers; Barclays and RBC are bookrunners. A Form S-3 shelf registration (including a prospectus) has been filed and declared effective by the SEC.

Positive

• Shelf registration on Form S-3 declared effective by the SEC
• Jefferies and J.P. Morgan appointed joint lead book-running managers

Negative

• Selling stockholders offering 10,000,000 shares
• Underwriters hold a 30-day option to buy up to 1,500,000 shares
• Company will not receive any proceeds from the offering

Insights

Capital Markets Analyst

Secondary offering of 10,000,000 shares by private equity holders; company receives no proceeds and underwriters have a 30-day option for 1,500,000 additional shares.

The transaction involves Aveanna Healthcare Holdings Inc. and selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC who have commenced a secondary offering of 10,000,000 shares of common stock on Oct. 21, 2025. The selling group will receive all net proceeds and the company will not receive any proceeds; Jefferies and J.P. Morgan lead-manage the deal and a shelf registration on Form S-3 is declared effective.

Key dependencies and risks include the offering size and the underwriters' 30-day option to purchase up to 1,500,000 additional shares, plus market reception at pricing and timing when the shares are sold. The company explicitly states it will not receive proceeds, which limits corporate impact to changes in freely tradable float and potential short-term supply pressure.

Watch for the prospectus supplement for offering price, final share count, and any lock-up or resale mechanics; these items typically appear within days to weeks after launch and determine the near-term market effect.

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC (the “Selling Stockholders”) have commenced a secondary offering of 10,000,000 shares of its common stock (the “Offering”). The Selling Stockholders will also grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders.

Jefferies LLC and J.P. Morgan Securities LLC are acting as joint lead book-running managers for the Offering. Barclays and RBC Capital Markets are acting as bookrunners for the Offering.

A shelf registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). Before you invest, you should read the prospectus in that registration statement, including the documents incorporated by reference therein, the accompanying prospectus supplement and other documents the Company has filed or will file with the SEC for more complete information about the Company and this Offering. You may get these documents, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.

Forward-Looking Statements

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2024 fiscal year filed with the SEC on March 13, 2025, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Matt Buckhalter
Chief Financial Officer
Ir@aveanna.com

FAQ

What did Aveanna (AVAH) announce on October 21, 2025?

Selling stockholders affiliated with J.H. Whitney commenced a secondary offering of 10,000,000 shares with a 30-day option for an additional 1,500,000 shares.

Will Aveanna (AVAH) receive proceeds from the October 21, 2025 offering?

No. The selling stockholders will receive all net proceeds and the company will not receive any proceeds.

Who are the lead managers for the AVAH secondary offering?

Jefferies LLC and J.P. Morgan Securities LLC are joint lead book-running managers; Barclays and RBC Capital Markets are bookrunners.

Is the AVAH offering registered with the SEC?

Yes. A shelf registration statement on Form S-3 (including a prospectus) has been filed and declared effective by the SEC.

How large is the underwriter overallotment for the AVAH offering?

Underwriters have a 30-day option to purchase up to 1,500,000 additional shares.